Cancer Stem Cell Resistance to Targeted Therapy
This book represents an updated summary of the state of the art of the characterization of cancer stem cell/cancer initiating cell (CSC/CIC) properties. Experts provide an overview of the definition and biological properties of CSCs/CICs as well as the ro
- PDF / 5,163,756 Bytes
- 267 Pages / 439.42 x 683.15 pts Page_size
- 12 Downloads / 226 Views
Cristina Maccalli Matilde Todaro Soldano Ferrone Editors
Cancer Stem Cell Resistance to Targeted Therapy
Resistance to Targeted Anti-Cancer Therapeutics Volume 19
Series Editor: Benjamin Bonavida
More information about this series at http://www.springer.com/series/11727
Cristina Maccalli • Matilde Todaro Soldano Ferrone Editors
Cancer Stem Cell Resistance to Targeted Therapy
Editors Cristina Maccalli Research Department Sidra Medicine Doha, Qatar Soldano Ferrone Department of Surgery Massachusetts General Hospital Harvard Medical School Boston, MA, USA
Matilde Todaro Department of DIBIMIS University of Palermo Laboratory of Cellular and Molecular Pathophysiology Palermo, Italy
ISSN 2196-5501 ISSN 2196-551X (electronic) Resistance to Targeted Anti-Cancer Therapeutics ISBN 978-3-030-16623-6 ISBN 978-3-030-16624-3 (eBook) https://doi.org/10.1007/978-3-030-16624-3 © Springer Nature Switzerland AG 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Aims and Scopes
Cells with stemness/cancer-initiating properties (CSCs/CICs) have been isolated from tumors with different histological properties. These cells have been shown to be responsible for tumor formation and progression and represent the component of tumor resistance to standard therapies and immunotherapy. During the last decades, targeted cancer therapies have been developed, including drugs, antibodies, chemical inhibitors, etc., targeting specific tumor-associated genes, antigens, and blood vessels that regulate tumor growth and progression. More recently, FDA- and EMA-approved immunotherapy agents targeting the host immune responses have shown clinical activity by improving patient’s survival. Targeted cancer therapi
Data Loading...
